Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues
Alessandro Conforti(University of Naples Federico II), Carlo Alviggi(University of Naples Federico II), Roberta Vallone, G. Nazzaro, Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pasquale De Rosa, Grazia Arpino(University of Naples Federico II), Giuseppe De Placido, Francesca Di Rella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mario Giuliano(Regione Campania), Sabino De Placido, Rossella Lauria, Irene De Santo(University of Naples Federico II), Mariavittoria Locci, Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Schettini(Target (United States))
Cited by 7
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413